iRhythm Technologies Q2 revenue beats estimates

iRhythm Holdings

31/07/2025 21:23

Overview

iRhythm Q2 2025 revenue rises 26.1% yr/yr, beating analyst expectations

Gross margin improves to 71.2%, reflecting operational efficiencies

Co partners with Lucem Health to enhance arrhythmia detection

Outlook

iRhythm projects 2025 revenue between $720 mln and $730 mln

Company expects 2025 adjusted EBITDA margin of 8.0% to 8.5%

Result Drivers

CORE MONITORING - Growth driven by demand in core long-term continuous monitoring business

ZIO AT DEMAND - Continued market penetration of Zio AT across major health systems

INTERNATIONAL MARKETS - Contribution from international markets supports revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$186.70 mln
$173.90 mln (12 Analysts)
Q2 Adjusted Net Income
-$10.20 mln
Q2 Net Income
-$14.20 mln
Q2 Gross Margin
71.2%
Q2 Gross Profit
$132.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for iRhythm Technologies Inc is $147.00, about 4.7% above its July 30 closing price of $140.08

Press Release: ID:nGNXKKk11

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)